Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753916 | 0.90 | ABCB1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL24233399 | 0.90 | AAK1 (0.52) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL5869075 | 0.90 | AAK1 (0.52) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL5868802 | 0.90 | ABCB1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL30059279 | 0.89 | CYP17A1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| Ammonia Solution, Strong SCHEMBL21835798 | 0.89 | ABCB1 (0.53) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL197036 | 0.89 | CYP17A1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL5868853 | 0.89 | AAK1 (0.51) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL3789925 | 0.89 | HDAC2 (0.51) | AAK1CYP17A1MAP4K4HDAC1HDAC2 | |
| SCHEMBL15160030 | 0.88 | GAA (0.52) | AAK1CYP17A1MAP4K4GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | AAK1 3562/4885CYP17A1 179/4885MAP4K4 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.